ImmuCell Corporation
ICCC
$6.52
$0.345.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.08% | 28.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.08% | 28.94% | |||
| Cost of Revenue | 4.45% | 1.91% | |||
| Gross Profit | 3.56% | 104.51% | |||
| SG&A Expenses | 6.37% | 1.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.38% | 2.07% | |||
| Operating Income | 8.67% | 278.88% | |||
| Income Before Tax | 178.31% | 174.33% | |||
| Income Tax Expenses | -68.33% | 361.54% | |||
| Earnings from Continuing Operations | 181.19% | 173.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 181.19% | 173.34% | |||
| EBIT | 8.67% | 278.88% | |||
| EBITDA | 5.37% | 1,598.80% | |||
| EPS Basic | 179.69% | 167.05% | |||
| Normalized Basic EPS | 10.17% | 221.08% | |||
| EPS Diluted | 177.78% | 164.00% | |||
| Normalized Diluted EPS | 10.17% | 221.08% | |||
| Average Basic Shares Outstanding | 0.51% | 9.44% | |||
| Average Diluted Shares Outstanding | 0.51% | 9.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||